Advanced glycation end products: A link between metabolic and endothelial dysfunction in polycystic ovary syndrome?

Metabolism: Clinical and Experimental

Volumn 64, Issue 11, 2015, Pages 1564-1573

  Pertynska Marczewska, Magdalena ^a   Diamanti Kandarakis, Evanthia ^b   Zhang, John ^c   Merhi, Zaher ^d  

^a Independent Consultant in Obstetrics and Gynecology   (United Kingdom)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c New Hope Fertility Center   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Advanced glycation end products; Endothelial dysfunction; Inflammation; Polycystic ovary syndrome; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ARGININE; INSULIN; METFORMIN;

ARTICLE; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; INSULIN RESISTANCE; METABOLIC DISORDER; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; METABOLISM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADIPOSITY; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ENDOTHELIUM, VASCULAR; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME;

EID: 84944441643     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2015.08.010     Document Type: Review

References (123)

1. A. Repaci, A. Gambineri, and R. Pasquali The role of low-grade inflammation in the polycystic ovary syndrome Mol Cell Endocrinol 335 2011 30 41
2. L.J. Moran, B.J. Strauss, and H.J. Teede Diabetes risk score in the diagnostic categories of polycystic ovary syndrome Fertil Steril 95 2011 1742 1748
3. F.R. Tehrani, M. Simbar, M. Tohidi, F. Hosseinpanah, and F. Azizi The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study Reprod Biol Endocrinol 9 2011 39 45
4. R. Azziz, K.S. Woods, R. Reyna, T.J. Key, E.S. Knochenhauer, and B.O. Yildiz The prevalence and features of the polycystic ovary syndrome in an unselected population J Clin Endocrinol Metab 89 2004 2745 2749
5. W.A. March, V.M. Moore, K.J. Willson, D.I. Phillips, R.J. Norman, and M.J. Davies The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria Hum Reprod 25 2010 544 551
6. R. Azziz PCOS: a diagnostic challenge Reprod Biomed Online 8 2004 644 648
7. E. Diamanti-Kandarakis, C.R. Kouli, A.T. Bergiele, F.A. Filandra, T.C. Tsianateli, G.G. Spina, and et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile J Clin Endocrinol Metab 84 1999 4006 4011
8. E. Carmina, and R.A. Lobo Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome Fertil Steril 82 2004 661 665
9. A.J. Cussons, B.G. Stuckey, and G.F. Watts Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives Atherosclerosis 185 2006 227 239
10. K. Berneis, M. Rizzo, M. Hersberger, G.B. Rini, G. Di Fede, I. Pepe, and et al. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome Int J Clin Pract 63 2009 56 62
11. M. Rizzo, and K. Berneis Low-density lipoprotein size and cardiovascular risk assessment QJM 99 2006 1 14
12. O. Valkenburg, R.P. Steegers-Theunissen, H.P. Smedts, G.M. Dallinga-Thie, B.C. Fauser, E.H. Westerveld, and et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study J Clin Endocrinol Metab 93 2008 470 476
13. D.S. Guzick Cardiovascular risk in women with polycystic ovarian syndrome Semin Reprod Endocrinol 14 1996 45 49
14. R.A. Wild, E. Carmina, E. Diamanti-Kandarakis, A. Dokras, H.F. Escobar-Morreale, W. Futterweit, and et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society J Clin Endocrinol Metab 95 2010 2038 2049
15. S. Benson, O.E. Janssen, S. Hahn, S. Tan, T. Dietz, K. Mann, and et al. Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome Brain Behav Immun 22 2008 177 184
16. M.P. Heron, and B.L. Smith Deaths: leading causes for 2003 Natl Vital Stat Rep 55 2007 1 92
17. A. Dokras Cardiovascular disease risk factors in polycystic ovary syndrome Semin Reprod Med 26 2008 39 44
18. R. Shroff, A. Kerchner, M. Maifeld, E.J. Van Beek, D. Jagasia, and A. Dokras Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis J Clin Endocrinol Metab 92 2007 4609 4614
19. M.A. Birdsall, C.M. Farquhar, and H.D. White Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization Ann Intern Med 126 1997 32 35
20. R.A. Wild, B. Grubb, A. Hartz, J.J. Van Nort, W. Bachman, and M. Bartholomew Clinical signs of androgen excess as risk factors for coronary artery disease Fertil Steril 54 1990 255 259
21. D.S. Guzick, E.O. Talbott, K. Sutton-Tyrrell, H.C. Herzog, L.H. Kuller, and S.K. Wolfson Jr. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study Am J Obstet Gynecol 174 1996 1224 1229 [discussion 9-32]
22. E.O. Talbott, D.S. Guzick, K. Sutton-Tyrrell, K.P. McHugh-Pemu, J.V. Zborowski, K.E. Remsberg, and et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women Arterioscler Thromb Vasc Biol 20 2000 2414 2421
23. E. Diamanti-Kandarakis, I. Katsikis, C. Piperi, E. Kandaraki, A. Piouka, A.G. Papavassiliou, and et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS) Clin Endocrinol (Oxf) 69 2008 634 641
24. J. Uribarri, W. Cai, M. Peppa, S. Goodman, L. Ferrucci, G. Striker, and et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging J Gerontol A: Biol Med Sci 62 2007 427 433
25. L. Zhang, M. Bukulin, E. Kojro, A. Roth, V.V. Metz, F. Fahrenholz, and et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases J Biol Chem 283 2008 35507 35516
26. C. Piperi, C. Adamopoulos, G. Dalagiorgou, E. Diamanti-Kandarakis, and A.G. Papavassiliou Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases J Clin Endocrinol Metab 97 2012 2231 2242
27. T. Koschinsky, C.J. He, T. Mitsuhashi, R. Bucala, C. Liu, C. Buenting, and et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy Proc Natl Acad Sci U S A 94 1997 6474 6479
28. H. Vlassara, and J. Uribarri Advanced glycation end products (AGE) and diabetes: cause, effect, or both? Curr Diab Rep 14 2014 453 468
29. H. Vlassara, and M.R. Palace Diabetes and advanced glycation endproducts J Intern Med 251 2002 87 101
30. E. Diamanti-Kandarakis, C. Piperi, P. Korkolopoulou, E. Kandaraki, G. Levidou, A. Papalois, and et al. Accumulation of dietary glycotoxins in the reproductive system of normal female rats J Mol Med 85 2007 1413 1420
31. C. Cerami, H. Founds, I. Nicholl, T. Mitsuhashi, D. Giordano, S. Vanpatten, and et al. Tobacco smoke is a source of toxic reactive glycation products Proc Natl Acad Sci U S A 94 1997 13915 13920
32. C.T. Pau, C.C. Keefe, and C.K. Welt Cigarette smoking, nicotine levels and increased risk for metabolic syndrome in women with polycystic ovary syndrome Gynecol Endocrinol 29 2013 551 555
33. E. Diamanti-Kandarakis, C. Piperi, E. Patsouris, P. Korkolopoulou, D. Panidis, L. Pawelczyk, and et al. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries Histochem Cell Biol 127 2007 581 589
34. A.Z. Kalea, A.M. Schmidt, and B.I. Hudson RAGE: a novel biological and genetic marker for vascular disease Clin Sci (Lond) 116 2009 621 637
35. S.F. Yan, R. Ramasamy, and A.M. Schmidt Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response J Mol Med (Berl) 87 2009 235 247
36. C.S. Haitoglou, E.C. Tsilibary, M. Brownlee, and A.S. Charonis Altered cellular interactions between endothelial cells and nonenzymaticallyglucosylatedlaminin/type IV collagen J Biol Chem 267 1992 12404 12407
37. F. Giacco, and M. Brownlee Oxidative stress and diabetic complications Circ Res 107 2010 1058 1070
38. R. Ramasamy, S.F. Yan, and A.M. Schmidt Advanced glycation endproducts: from precursors to RAGE: round and round we go Amino Acids 42 2012 1151 1161
39. S.F. Yan, V. D'Agati, A.M. Schmidt, and R. Ramasamy Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging Curr Mol Med 7 2007 699 710
40. A. Raucci, S. Cugusi, A. Antonelli, S.M. Barabino, L. Monti, A. Bierhaus, and et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) FASEB J 22 2008 3716 3727
41. C. Falcone, S. Bozzini, L. Guasti, A. D'Angelo, A.C. Capettini, E.M. Paganini, and et al. Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease ScientificWorldJournal 2013 2013 584504 584510
42. F. Giallauria, F. Orio, S. Palomba, G. Lombardi, A. Colao, and C. Vigorito Cardiovascular risk in women with polycystic ovary syndrome J Cardiovasc Med (Hagerstown) 9 2008 987 992
43. L.K. Hoffman, and D.A. Ehrmann Cardiometabolic features of polycystic ovary syndrome Nat Clin Pract Endocrinol Metab 4 2008 215 222
44. Z.M. van der Spuy, and S.J. Dyer The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome Best Pract Res Clin Obstet Gynaecol 18 2004 755 771
45. N. Sekar, J.C. Garmey, and J.D. Veldhuis Mechanisms underlying the steroidogenic synergy of insulin and luteinizing hormone in porcine granulosa cells: joint amplification of pivotal sterol-regulatory genes encoding the low-density lipoprotein (LDL) receptor, steroidogenic acute regulatory (stAR) protein and cytochrome P450 side-chain cleavage (P450scc) enzyme Mol Cell Endocrinol 159 2000 25 35
46. S. Jonard, and D. Dewailly The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest Hum Reprod Update 10 2004 107 117
47. P. Morley, F.R. Calaresu, G.J. Barbe, and D.T. Armstrong Insulin enhances luteinizing hormone-stimulated steroidogenesis by porcine theca cells Biol Reprod 40 1989 735 743
48. F. Gonzalez Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction Steroids 77 2012 300 305
49. S. Taponen, H. Martikainen, M.R. Jarvelin, J. Laitinen, A. Pouta, A.L. Hartikainen, and et al. Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study J Clin Endocrinol Metab 88 2003 141 147
50. E. Diamanti-Kandarakis, G. Argyrakopoulou, F. Economou, E. Kandaraki, and M. Koutsilieris Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome (PCOS) J Steroid Biochem Mol Biol 109 2008 242 246
51. E. Codner, and H.F. Escobar-Morreale Clinical review: Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus J Clin Endocrinol Metab 92 2007 1209 1216
52. J.E. Nestler, L.P. Powers, D.W. Matt, K.A. Steingold, S.R. Plymate, R.S. Rittmaster, and et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome J Clin Endocrinol Metab 72 1991 83 89
53. R.S. Legro, C.L. Gnatuk, A.R. Kunselman, and A. Dunaif Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study J Clin Endocrinol Metab 90 2005 3236 3242
54. E. Diamanti-Kandarakis, C. Piperi, A. Kalofoutis, and G. Creatsas Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome Clin Endocrinol (Oxf) 62 2005 37 43
55. E. Tantalaki, C. Piperi, S. Livadas, A. Kollias, C. Adamopoulos, A. Koulouri, and et al. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS) Hormones (Athens) 13 2014 65 73
56. P. Altieri, C. Cavazza, F. Pasqui, A.M. Morselli, A. Gambineri, and R. Pasquali Dietary habits and their relationship with hormones and metabolism in overweight and obese women with polycystic ovary syndrome Clin Endocrinol (Oxf) 78 2013 52 59
57. A. Cassese, I. Esposito, F. Fiory, A.P. Barbagallo, F. Paturzo, P. Mirra, and et al. In skeletal muscle advanced glycation end products (AGEs) inhibit insulin action and induce the formation of multimolecular complexes including the receptor for AGEs J Biol Chem 283 2008 36088 36099
58. C. Ott, K. Jacobs, E. Haucke, A. Navarrete Santos, T. Grune, and A. Simm Role of advanced glycation end products in cellular signaling Redox Biol 2 2014 411 429
59. R. Pasquali, E. Stener-Victorin, B.O. Yildiz, A.J. Duleba, K. Hoeger, H. Mason, and et al. PCOS Forum: research in polycystic ovary syndrome today and tomorrow Clin Endocrinol (Oxf) 74 2011 424 433
60. A. Dunaif, X. Wu, A. Lee, and E. Diamanti-Kandarakis Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS) Am J Physiol Endocrinol Metab 281 2001 E392 E399
61. H. Sano, T. Higashi, K. Matsumoto, J. Melkko, Y. Jinnouchi, K. Ikeda, and et al. Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced glycation end products J Biol Chem 273 1998 8630 8637
62. C. Tatone, and F. Amicarelli The aging ovary - the poor granulosa cells Fertil Steril 99 2013 12 17
63. E. Diamanti-Kandarakis, A. Chatzigeorgiou, E. Papageorgiou, D. Koundouras, and M. Koutsilieris Advanced glycation end-products and insulin signaling in granulosa cells Exp Biol Med (Maywood) 2015 [pii: 1535370215584937, Epub ahead of print]
64. Z. Merhi, M. Irani, A.D. Doswell, and J. Ambroggio Follicular fluid soluble receptor for advanced glycation end-products (sRAGE): a potential indicator of ovarian reserve J Clin Endocrinol Metab 99 2014 E226 E233
65. Z. Merhi Advanced glycation end products and their relevance in female reproduction Hum Reprod 29 2014 135 145
66. E. Diamanti-Kandarakis, and A. Dunaif Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications Endocr Rev 33 2012 981 1030
67. H.A. Beydoun, M.A. Beydoun, N. Wiggins, and L. Stadtmauer Relationship of obesity-related disturbances with LH/FSH ratio among post-menopausal women in the United States Maturitas 71 2012 55 61
68. M. Magnotti, and W. Futterweit Obesity and the polycystic ovary syndrome Med Clin North Am 91 2007 1151 1168 [ix-x]
69. G. Garruti, R. Depalo, M.G. Vita, F. Lorusso, F. Giampetruzzi, A.B. Damato, and et al. Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment Reprod Biomed Online 19 2009 552 563
70. H.J. Teede, A.E. Joham, E. Paul, L.J. Moran, D. Loxton, D. Jolley, and et al. Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women Obesity (Silver Spring) 21 2013 1526 1532
71. N.K. Stepto, S. Cassar, A.E. Joham, S.K. Hutchison, C.L. Harrison, R.F. Goldstein, and et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp Hum Reprod 28 2013 777 784
72. E. Diamanti-Kandarakis, A. Piouka, S. Livadas, C. Piperi, I. Katsikis, A.G. Papavassiliou, and et al. Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome Eur J Endocrinol 160 2009 847 853
73. W. Cai, M. Ramdas, L. Zhu, X. Chen, G.E. Striker, and H. Vlassara Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1 Proc Natl Acad Sci U S A 109 2012 15888 15893
74. J. Uribarri, W. Cai, M. Ramdas, S. Goodman, R. Pyzik, X. Chen, and et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1 Diabetes Care 34 2011 1610 1616
75. A.B. Mark, M.W. Poulsen, S. Andersen, J.M. Andersen, M.J. Bak, C. Ritz, and et al. Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women Diabetes Care 37 2014 88 95
76. H. Vlassara, and G.E. Striker AGE restriction in diabetes mellitus: a paradigm shift Nat Rev Endocrinol 7 2011 526 539
77. E. Diamanti-Kandarakis, K. Alexandraki, C. Piperi, A. Aessopos, T. Paterakis, I. Katsikis, and et al. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome Metabolism 56 2007 129 134
78. M. Li, M. Yang, X. Zhou, X. Fang, W. Hu, W. Zhu, and et al. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome J Clin Endocrinol Metab 100 2015 1485 1493
79. A. Masha, C. Manieri, S. Dinatale, G.A. Bruno, E. Ghigo, and V. Martina Prolonged treatment with N-acetylcysteine and L-arginine restores gonadal function in patients with polycystic ovary syndrome J Endocrinol Invest 32 2009 870 872
80. H. Kahal, M. Aye, A.S. Rigby, T. Sathyapalan, R.J. England, and S.L. Atkin The effect of parathyroidectomy on neuropsychological symptoms and biochemical parameters in patients with asymptomatic primary hyperparathyroidism Clin Endocrinol (Oxf) 76 2012 196 200
81. X. Jia, T. Chang, T.W. Wilson, and L. Wu Methylglyoxal mediates adipocyte proliferation by increasing phosphorylation of Akt1 PLoS One 7 2012 e36610 e36618
82. J. Uribarri, W. Cai, M. Woodward, E. Tripp, L. Goldberg, R. Pyzik, and et al. Elevated serum advanced glycation endproducts in obese indicate risk for the metabolic syndrome: a link between healthy and unhealthy obesity? J Clin Endocrinol Metab 100 2015 1957 1966
83. L. Teillet, P. Verbeke, S. Gouraud, H. Bakala, C. Borot-Laloi, D. Heudes, and et al. Food restriction prevents advanced glycation end product accumulation and retards kidney aging in lean rats J Am Soc Nephrol 11 2000 1488 1497
84. A. Gugliucci, K. Kotani, J. Taing, Y. Matsuoka, Y. Sano, M. Yoshimura, and et al. Short-term low calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults Ann Nutr Metab 54 2009 197 201
85. K.H. Gaens, G.H. Goossens, P.M. Niessen, M.M. van Greevenbroek, C.J. van der Kallen, H.W. Niessen, and et al. Nepsilon-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance Arterioscler Thromb Vasc Biol 34 2014 1199 1208
86. Y. Yamamoto, and H. Yamamoto RAGE-Mediated Inflammation, Type 2 Diabetes, and Diabetic Vascular Complication Front Endocrinol (Lausanne) 4 2013 105 107
87. H. Ueno, H. Koyama, T. Shoji, M. Monden, S. Fukumoto, S. Tanaka, and et al. Receptor for advanced glycation end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in apoE-deficient mouse Atherosclerosis 211 2010 431 436
88. C.T. He, C.H. Lee, C.H. Hsieh, and F.C. Hsiao Soluble form of receptor for advanced glycation end products is associated with obesity and metabolic syndrome in adolescents Int J Endocrinol 2014 2014 657607 657613
89. K.E. Davis, C. Prasad, P. Vijayagopal, S. Juma, and V. Imrhan Serum soluble receptor for advanced glycation end products correlates inversely with measures of adiposity in young adults Nutr Res 34 2014 478 485
90. J.M. Brix, F. Hollerl, H.P. Kopp, G.H. Schernthaner, and G. Schernthaner The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesity Int J Obes (Lond) 36 2012 1412 1417
91. N. Phelan, A. O'Connor, T. Kyaw Tun, N. Correia, G. Boran, H.M. Roche, and et al. Hormonal and metabolic effects of polyunsaturated fatty acids in young women with polycystic ovary syndrome: results from a cross-sectional analysis and a randomized, placebo-controlled, crossover trial Am J Clin Nutr 93 2011 652 662
92. M. Rafraf, E. Mohammadi, M. Asghari-Jafarabadi, and L. Farzadi Omega-3 fatty acids improve glucose metabolism without effects on obesity values and serum visfatin levels in women with polycystic ovary syndrome J Am Coll Nutr 31 2012 361 368
93. W. Mak, and A. Dokras Polycystic ovarian syndrome and the risk of cardiovascular disease and thrombosis Semin Thromb Hemost 35 2009 613 620
94. R. Karoli, J. Fatima, Z. Siddiqi, P. Vatsal, A.R. Sultania, and S. Maini Study of early atherosclerotic markers in women with polycystic ovary syndrome Indian J Endocrinol Metab 16 2012 1004 1008
95. F. Orio Jr., S. Palomba, T. Cascella, F. Manguso, L. Vuolo, D. Tafuri, and et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome J Clin Endocrinol Metab 89 2004 4588 4593
96. A.K. Guleria, S.K. Syal, A. Kapoor, S. Kumar, P. Tiwari, and P. Dabadghao Cardiovascular disease risk in young Indian women with polycystic ovary syndrome Gynecol Endocrinol 30 2014 26 29
97. H.W. Teng, Y.W. Chien, M.I. Hsu, and C.I. Chen The relationship between carotid intima-media thickness and endogenous androgens in young women with polycystic ovary syndrome in Taiwan Gynecol Endocrinol 29 2013 238 241
98. V.S. Sprung, G. Atkinson, D.J. Cuthbertson, C.J. Pugh, N. Aziz, D.J. Green, and et al. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies Clin Endocrinol (Oxf) 78 2013 438 446
99. S. Rajendran, S.R. Willoughby, W.P. Chan, E.A. Liberts, T. Heresztyn, M. Saha, and et al. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects Atherosclerosis 204 2009 509 514
100. E.A. Lambert, H. Teede, C.I. Sari, E. Jona, S. Shorakae, K. Woodington, and et al. Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance Clin Endocrinol (Oxf) 2015 10.1111/cen.12803 [Epub ahead of print]
101. A.A. Rizvi Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts Am J Med Sci 338 2009 310 318
102. W.P. Chan, D.T. Ngo, A.L. Sverdlov, S. Rajendran, I. Stafford, T. Heresztyn, and et al. Premature aging of cardiovascular/platelet function in polycystic ovarian syndrome Am J Med 126 2013 640e1 640e7
103. R. Corti, R. Hutter, J.J. Badimon, and V. Fuster Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis J Thromb Thrombolysis 17 2004 35 44
104. E. Diamanti-Kandarakis, K. Alexandraki, C. Piperi, A. Protogerou, I. Katsikis, T. Paterakis, and et al. Inflammatory and endothelial markers in women with polycystic ovary syndrome Eur J Clin Invest 36 2006 691 697
105. C. Christakou, F. Economou, S. Livadas, C. Piperi, C. Adamopoulos, E. Marinakis, and et al. Strong and positive association of endothelin-1 with AGEs in PCOS: a causal relationship or a bystander? Hormones (Athens) 10 2011 292 297
106. D. Kocer, F. Bayram, and H. Diri The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome Gynecol Endocrinol 30 2014 367 371
107. F. Piarulli, A. Lapolla, E. Ragazzi, A. Susana, A. Sechi, L. Nollino, and et al. Role of endogenous secretory RAGE (esRAGE) in defending against plaque formation induced by oxidative stress in type 2 diabetic patients Atherosclerosis 226 2013 252 257
108. L. Lu, L.J. Pu, Q. Zhang, L.J. Wang, S. Kang, R.Y. Zhang, and et al. Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes Atherosclerosis 206 2009 540 545
109. W.H. Peng, L. Lu, J. Hu, X.X. Yan, Q. Zhang, R.Y. Zhang, and et al. Decreased serum esRAGE level is associated with angiographically determined coronary plaque progression in diabetic patients Clin Biochem 42 2009 1252 1259
110. N. Tanaka, H. Yonekura, S. Yamagishi, H. Fujimori, Y. Yamamoto, and H. Yamamoto The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells J Biol Chem 275 2000 25781 25790
111. H.F. Escobar-Morreale, R.M. Calvo, J. Sancho, and J.L. San Millan TNF-alpha and hyperandrogenism: a clinical, biochemical, and molecular genetic study J Clin Endocrinol Metab 86 2001 3761 3767
112. J.H. Yun, J.W. Choi, K.J. Lee, J.S. Shin, and K.H. Baek The promoter -1031(T/C) polymorphism in tumor necrosis factor-alpha associated with polycystic ovary syndrome Reprod Biol Endocrinol 9 2011 131 136
113. C.E. Pepene, I.R. Ilie, I. Marian, and I. Duncea Circulating osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction Eur J Endocrinol 164 2011 61 68
114. K.A. Toulis, D.G. Goulis, G. Mintziori, C.A. Venetis, E.M. Kolibianakis, and B.C. Tarlatzis Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome Hum Reprod Update 17 2011 741 760
115. M.P. Siroen, T. Teerlink, R.J. Nijveldt, H.A. Prins, M.C. Richir, and P.A. van Leeuwen The clinical significance of asymmetric dimethylarginine Annu Rev Nutr 26 2006 203 228
116. V. Raptis, S. Kapoulas, and D. Grekas Role of asymmetrical dimethylarginine in the progression of renal disease Nephrology (Carlton) 18 2013 11 21
117. U.N. Das, G. Repossi, A. Dain, and A.R. Eynard L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes Front Biosci (Landmark Ed) 16 2011 13 20
118. R.H. Boger, S.M. Bode-Boger, A. Szuba, P.S. Tsao, J.R. Chan, O. Tangphao, and et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia Circulation 98 1998 1842 1847
119. P. Lundman, M.J. Eriksson, M. Stuhlinger, J.P. Cooke, A. Hamsten, and P. Tornvall Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine J Am Coll Cardiol 38 2001 111 116
120. S.M. Bode-Boger, F. Scalera, and L.J. Ignarro The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio Pharmacol Ther 114 2007 295 306
121. D.T. Ngo, W.P. Chan, S. Rajendran, T. Heresztyn, A. Amarasekera, A.L. Sverdlov, and et al. Determinants of insulin responsiveness in young women: Impact of polycystic ovarian syndrome, nitric oxide, and vitamin D Nitric Oxide 25 2011 326 330
122. I. Turkcuoglu, Y. Engin-Ustun, F. Turan, Z. Kali, A.B. Karabulut, M. Meydanli, and et al. Evaluation of asymmetric dimethylarginine, nitric oxide levels and associated independent variables in obese and lean patients with polycystic ovarian syndrome Gynecol Endocrinol 27 2011 609 614
123. D. Heutling, H. Schulz, I. Nickel, J. Kleinstein, P. Kaltwasser, S. Westphal, and et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment J Clin Endocrinol Metab 93 2008 82 90